Guidelines and legislation for dye house effluents

C Hessel, C Allegre, M Maisseu, F Charbit… - Journal of environmental …, 2007 - Elsevier
Increasing attention has been paid over the years to the environmental problems related to
industrial activities. Environmental standards have been established and control organisms …

[HTML][HTML] Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial) …

TK Choueiri, C Hessel, S Halabi, B Sanford… - European journal of …, 2018 - Elsevier
Background The randomised phase 2 CABOSUN trial comparing cabozantinib with sunitinib
as initial therapy for advanced renal cell carcinoma (RCC) of intermediate or poor risk met …

Two-dimensional carbon leading to new photoconversion processes

H Tang, CM Hessel, J Wang, N Yang, R Yu… - Chemical Society …, 2014 - pubs.rsc.org
… Pristine graphene can be functionalized with organic molecules by the addition of free
radicals to sp 2 carbon atoms of graphene, or the addition of dienophiles to CC bonds. These …

[HTML][HTML] Cabozantinib in patients with advanced and progressing hepatocellular carcinoma

…, MH Ryu, AP Venook, C Hessel… - … England Journal of …, 2018 - Mass Medical Soc
Background Cabozantinib inhibits tyrosine kinases, including vascular endothelial growth
factor receptors 1, 2, and 3, MET, and AXL, which are implicated in the progression of …

[HTML][HTML] Cabozantinib versus everolimus in advanced renal-cell carcinoma

…, C Hessel, C Scheffold… - … England Journal of …, 2015 - Mass Medical Soc
Background Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets
vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which …

[HTML][HTML] Cabozantinib in progressive medullary thyroid cancer

…, EEW Cohen, LJ Wirth, H Ali, C Hessel… - Journal of clinical …, 2013 - ncbi.nlm.nih.gov
Purpose Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET),
vascular endothelial growth factor receptor 2, and rearranged during transfection (…

Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

…, DF McDermott, DT Aftab, C Hessel, C Scheffold… - The lancet …, 2016 - thelancet.com
c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell … c-Met
is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. …

Copper selenide nanocrystals for photothermal therapy

CM Hessel, VP Pattani, M Rasch, MG Panthani… - Nano …, 2011 - ACS Publications
Ligand-stabilized copper selenide (Cu 2-x Se) nanocrystals, approximately 16 nm in diameter,
were synthesized by a colloidal hot injection method and coated with amphiphilic polymer…

Occupational therapy for independent-living older adults: A randomized controlled trial

…, D Mandel, J Hay, K Josephson, B Cherry, C Hessel… - Jama, 1997 - jamanetwork.com
Context. —Preventive health programs may mitigate against the health risks of older
adulthood. Objective. —To evaluate the effectiveness of preventive occupational therapy (OT) …

α-Fe 2 O 3 multi-shelled hollow microspheres for lithium ion battery anodes with superior capacity and charge retention

S Xu, CM Hessel, H Ren, R Yu, Q Jin, M Yang… - Energy & …, 2014 - pubs.rsc.org
Multi-shelled α-Fe2O3 hollow microspheres were synthesized using carbonaceous
microsphere sacrificial templates and utilized for high capacity anode materials in lithium ion …